Stewart Washer

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Xceed Capital Ltd. is engaged in the manufacture of pharmaceutical products. The company's business includes chemical segment which is a supplier of organo-boron compounds. Xceed Capital is headquartered in Perth, Australia.

Xceed Capital Ltd. is engaged in the manufacture of pharmaceutical products. The company's business includes chemical segment which is a supplier of organo-boron compounds. Xceed Capital is headquartered in Perth, Australia.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand.

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Xceed Capital Ltd. is engaged in the manufacture of pharmaceutical products. The company's business includes chemical segment which is a supplier of organo-boron compounds. Xceed Capital is headquartered in Perth, Australia.